NVO - Novo Nordisk A/S

NYSE - NYSE Delayed price. Currency in USD
Show:
Income statement
Balance sheet
Cash flow
Annual

Income statement

Currency in DKK. All numbers in thousands
Breakdown
ttm
30/12/2018
30/12/2017
30/12/2016
30/12/2015
Total revenue
119,336,000
111,831,000
111,696,000
111,780,000
107,927,000
Cost of revenue
19,309,000
17,617,000
17,632,000
17,183,000
16,188,000
Gross profit
100,027,000
94,214,000
94,064,000
94,597,000
91,739,000
Operating expenses
Research development
14,380,000
14,805,000
14,014,000
14,563,000
13,608,000
Selling general and administrative
35,056,000
33,313,000
32,124,000
32,339,000
32,169,000
Total operating expenses
48,634,000
46,966,000
45,097,000
46,165,000
42,295,000
Operating income or loss
51,393,000
47,248,000
48,967,000
48,432,000
49,444,000
Interest expense
1,887,000
85,000
90,000
65,000
67,000
Total other income/expenses net
-
473,000
-198,000
-536,000
-5,869,000
Income before tax
47,844,000
47,615,000
48,680,000
47,798,000
43,483,000
Income tax expense
9,113,000
8,987,000
10,550,000
9,873,000
8,623,000
Income from continuing operations
38,731,000
38,628,000
38,130,000
37,925,000
34,860,000
Net income
38,731,000
38,628,000
38,130,000
37,925,000
34,860,000
Net income available to common shareholders
38,731,000
38,628,000
38,130,000
37,925,000
34,860,000
Reported EPS
Basic
-
15.96
15.42
14.99
13.56
Diluted
-
15.93
15.39
14.96
13.52
Weighted average shares outstanding
Basic
-
2,419,603
2,473,218
2,529,945
2,570,796
Diluted
-
2,424,417
2,478,093
2,534,729
2,578,402
EBITDA
-
51,625,000
51,952,000
51,056,000
46,509,000
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more